These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Leuprolide: a review of its effects in animals and man. Drago JR; Rohner T; Santen R; Manni A; Lipton A; Harvey H; English H Br J Clin Pract Suppl; 1985 Mar; 37():4-7, 16-9. PubMed ID: 3931664 [No Abstract] [Full Text] [Related]
24. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. Leuprolide Study Group N Engl J Med; 1984 Nov; 311(20):1281-6. PubMed ID: 6436700 [TBL] [Abstract][Full Text] [Related]
25. Pharmaceutical manipulation of leuprorelin acetate to improve clinical performance. Toguchi H J Int Med Res; 1990; 18 Suppl 1():35-41. PubMed ID: 2138986 [TBL] [Abstract][Full Text] [Related]
26. Leuprolide versus diethylstilbestrol for previously untreated stage D2 prostate cancer. Results of a prospectively randomized trial. Garnick MB Urology; 1986 Jan; 27(1 Suppl):21-8. PubMed ID: 3079935 [TBL] [Abstract][Full Text] [Related]
27. The treatment of prostatic cancer by LH-RH agonist. Imai K; Yamanaka H; Yuasa H; Yoshida M; Asano M; Kaetsu I Prog Clin Biol Res; 1987; 243A():429-34. PubMed ID: 3116552 [No Abstract] [Full Text] [Related]
28. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain? Cox MC; Scripture CD; Figg WD Expert Rev Anticancer Ther; 2005 Aug; 5(4):605-11. PubMed ID: 16111462 [TBL] [Abstract][Full Text] [Related]
29. Leuprolide for prostate cancer. Med Lett Drugs Ther; 1985 Aug; 27(694):71-2. PubMed ID: 2410765 [No Abstract] [Full Text] [Related]
30. [Hormone kinetics in suppression with monthly Enantone depot preparations]. Schilling A Urologe A; 1991 May; 30(3 Suppl):9. PubMed ID: 1746075 [No Abstract] [Full Text] [Related]
32. Effect of the intranasal administration of LHRH superanalogue on endogenous LHRH in humans. Matsubara M; Koyanagawa Y; Nakagawa K Horm Metab Res; 1989 Feb; 21(2):104-5. PubMed ID: 2498194 [No Abstract] [Full Text] [Related]
33. Phase III studies in prostatic cancer with leuprolide acetate. Seely JH J Androl; 1987; 8(1):S23-6. PubMed ID: 3104263 [No Abstract] [Full Text] [Related]
34. Expert opinion on 6-monthly luteinizing hormone-releasing hormone agonist treatment with the single-sphere depot system for prostate cancer. Schulman C; Alcaraz A; Berges R; Montorsi F; Teillac P; Tombal B BJU Int; 2007 Jul; 100 Suppl 1():1-5. PubMed ID: 17593201 [No Abstract] [Full Text] [Related]
35. Clinical experience with leuprorelin acetate before radiotherapy for prostatic cancer. Bourdin S; Karam G; Clemain P; Bouchot O; Peuvrel P; Lacoste J; Auvigne J J Int Med Res; 1990; 18 Suppl 1():74-8. PubMed ID: 2108888 [TBL] [Abstract][Full Text] [Related]
37. Controlled-release of leuprolide acetate from polylactic acid or copoly(lactic/glycolic) acid microcapsules: influence of molecular weight and copolymer ratio of polymer. Ogawa Y; Yamamoto M; Takada S; Okada H; Shimamoto T Chem Pharm Bull (Tokyo); 1988 Apr; 36(4):1502-7. PubMed ID: 3138032 [No Abstract] [Full Text] [Related]
38. Leuprolide: a review of its effects in comparison with diethylstilboestrol in the treatment of advanced cancer of the prostate. Garnick MB; Glode LM; Smith JA; Max DT Br J Clin Pract Suppl; 1985 Mar; 37():8-12, 20-4. PubMed ID: 3931665 [No Abstract] [Full Text] [Related]
39. New prostate cancer drugs: few CV effects? Henahan J JAMA; 1983 Oct; 250(16):2097-9. PubMed ID: 6413706 [No Abstract] [Full Text] [Related]